Structure-activity relationship analysis of peptides targeting the EphA2 receptor

Biochemistry

Volumn 49, Issue 31, 2010, Pages 6687-6695

  Mitra, Sayantan ^a   Duggineni, Srinivas ^a,c   Koolpe, Mitchell ^d   Zhu, Xuejun ^a   Huang, Ziwei ^a,b   Pasquale, Elena B ^a,b  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AFFINITY RECEPTORS; CANCER CELLS; CELL CULTURE MEDIUMS; IMAGING AGENT; INHIBITION OF TUMOR GROWTH; LIGAND BINDING DOMAIN; PHYSIOLOGICAL LIGANDS; RECEPTOR TYROSINE KINASE; SIGNALING PATHWAYS; STRUCTURE ACTIVITY RELATIONSHIPS; THERAPEUTIC TARGETS; TUMOR CELLS;

AMINO ACIDS; CELL CULTURE; LIGANDS; ORGANIC ACIDS; PHOSPHATASES; TUMORS;

PEPTIDES;

EPHRIN A1; EPHRIN RECEPTOR A2;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER INHIBITION; DRUG RECEPTOR BINDING; LIGAND BINDING; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; NEOPLASM PROTEINS; OLIGOPEPTIDES; PROTEIN BINDING; RECEPTOR, EPHA2; RECEPTORS, EPH FAMILY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955252631     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi1006223     Document Type: Article

References (47)

1. Ireton, R. C. and Chen, J. (2005) EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics Curr. Cancer Drug Targets 5, 149-157
2. Landen, C. N., Kinch, M. S., and Sood, A. K. (2005) EphA2 as a target for ovarian cancer therapy Expert Opin. Ther. Targets 9, 1179-1187
3. Wykosky, J. and Debinski, W. (2008) The EphA2 receptor and ephrinA1 ligand in solid tumors: Function and therapeutic targeting Mol. Cancer Res. 6, 1795-1806
4. Ogawa, K., Pasqualini, R., Lindberg, R. A., Kain, R., Freeman, A. L., and Pasquale, E. B. (2000) The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization Oncogene 19, 6043-6052
5. Brantley-Sieders, D. M. and Chen, J. (2004) Eph receptor tyrosine kinases in angiogenesis: From development to disease Angiogenesis 7, 17-28 (Pubitemid 39127767)
6. Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., and Clark, E. (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection Cancer Res. 67, 2226-2238 (Pubitemid 46424242)
7. Wang, X. D., Reeves, K., Luo, F. R., Xu, L. A., Lee, F., Clark, E., and Huang, F. (2007) Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: Rationale for patient selection and efficacy monitoring Genome Biol. 8, R255
8. Zelinski, D. P., Zantek, N. D., Stewart, J. C., Irizarry, A. R., and Kinch, M. S. (2001) EphA2 Overexpression Causes Tumorigenesis of Mammary Epithelial Cells Cancer Res. 61, 2301-2306
9. Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., and Whang, E. E. (2004) EphA2: A determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma Oncogene 23, 1448-1456
10. Landen, C. N., Jr., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., and Sood, A. K. (2005) Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery Cancer Res. 65, 6910-6918
11. Miao, H., Wei, B. R., Peehl, D. M., Li, Q., Alexandrou, T., Schelling, J. R., Rhim, J. S., Sedor, J. R., Burnett, E., and Wang, B. C. (2001) Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway Nat. Cell Biol. 3, 527-530
12. Pasquale, E. B. (2008) Eph-ephrin bidirectional signaling in physiology and disease Cell 133, 38-52
13. Miao, H., Li, D. Q., Mukherjee, A., Guo, H., Petty, A., Cutter, J., Basilion, J. P., Sedor, J., Wu, J., Danielpour, D., Sloan, A. E., Cohen, M. L., and Wang, B. (2009) EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt Cancer Cell 16, 9-20
14. Pasquale, E. B. (2005) Eph receptor signalling casts a wide net on cell behaviour Nat. Rev. Mol. Cell Biol. 6, 462-475
15. Menges, C. W. and McCance, D. J. (2008) Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor Oncogene 27, 2934-2940
16. Chen, J., Zhuang, G., Frieden, L., and Debinski, W. (2008) Eph receptors and Ephrins in cancer: Common themes and controversies Cancer Res. 68, 10031-10033
17. Coffman, K. T., Hu, M., Carles-Kinch, K., Tice, D., Donacki, N., Munyon, K., Kifle, G., Woods, R., Langermann, S., Kiener, P. A., and Kinch, M. S. (2003) Differential EphA2 Epitope Display on Normal versus Malignant Cells Cancer Res. 63, 7907-7912
18. Noblitt, L. W., Bangari, D. S., Shukla, S., Knapp, D. W., Mohammed, S., Kinch, M. S., and Mittal, S. K. (2004) Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1 Cancer Gene Ther. 11, 757-766
19. Landen, C. N., Jr., Lu, C., Han, L. Y., Coffman, K. T., Bruckheimer, E., Halder, J., Mangala, L. S., Merritt, W. M., Lin, Y. G., Gao, C., Schmandt, R., Kamat, A. A., Li, Y., Thaker, P., Gershenson, D. M., Parikh, N. U., Gallick, G. E., Kinch, M. S., and Sood, A. K. (2006) Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer J. Natl. Cancer Inst. 98, 1558-1570
20. Wesa, A. K., Herrem, C. J., Mandic, M., Taylor, J. L., Vasquez, C., Kawabe, M., Tatsumi, T., Leibowitz, M. S., Finke, J. H., Bukowski, R. M., Bruckheimer, E., Kinch, M. S., and Storkus, W. J. (2008) Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists J. Immunol. 181, 7721-7727
21. Bruckheimer, E. M., Fazenbaker, C. A., Gallagher, S., Mulgrew, K., Fuhrmann, S., Coffman, K. T., Walsh, W., Ready, S., Cook, K., Damschroder, M., Kinch, M., Kiener, P. A., Woods, R., Gao, C., Dall'Acqua, W., Wu, H., and Coats, S. (2009) Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors Neoplasia 11, 509-517 (502 p following 517)
22. Pasquale, E. B. (2010) Eph receptors and ephrins in cancer: Bidirectional signaling and beyond Nat. Rev. Cancer 10, 165-180
23. Hammond, S. A., Lutterbuese, R., Roff, S., Lutterbuese, P., Schlereth, B., Bruckheimer, E., Kinch, M. S., Coats, S., Baeuerle, P. A., Kufer, P., and Kiener, P. A. (2007) Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct Cancer Res. 67, 3927-3935
24. Gobin, A. M., Moon, J. J., and West, J. L. (2008) EphrinA I-targeted nanoshells for photothermal ablation of prostate cancer cells Int. J. Nanomed. 3, 351-358
25. Wykosky, J., Gibo, D. M., and Debinski, W. (2007) A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor-expressing tumor cells Mol. Cancer Ther. 6, 3208-3218
26. Jackson, D., Gooya, J., Mao, S., Kinneer, K., Xu, L., Camara, M., Fazenbaker, C., Fleming, R., Swamynathan, S., Meyer, D., Senter, P. D., Gao, C., Wu, H., Kinch, M., Coats, S., Kiener, P. A., and Tice, D. A. (2008) A Human Antibody-Drug Conjugate Targeting EphA2 Inhibits Tumor Growth in Vivo Cancer Res. 68, 9367-9374
27. Lee, J. W., Han, H. D., Shahzad, M. M., Kim, S. W., Mangala, L. S., Nick, A. M., Lu, C., Langley, R. R., Schmandt, R., Kim, H. S., Mao, S., Gooya, J., Fazenbaker, C., Jackson, D., Tice, D. A., Landen, C. N., Coleman, R. L., and Sood, A. K. (2009) EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma J. Natl. Cancer Inst. 101, 1193-1205
28. Cai, W., Ebrahimnejad, A., Chen, K., Cao, Q., Li, Z. B., Tice, D. A., and Chen, X. (2007) Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice Eur. J. Nucl. Med. Mol. Imaging 34, 2024-2036
29. Koolpe, M., Dail, M., and Pasquale, E. B. (2002) An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor J. Biol. Chem. 277, 46974-46979
30. Scarberry, K. E., Dickerson, E. B., McDonald, J. F., and Zhang, Z. J. (2008) Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells J. Am. Chem. Soc. 130, 10258-10262
31. Scarberry, K. E., Dickerson, E. B., Zhang, Z. J., Benigno, B. B., and McDonald, J. F. (2010) Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles Nanomedicine 6, 399-408
32. Dickerson, E. B., Blackburn, W. H., Smith, M. H., Kapa, L. B., Lyon, L. A., and McDonald, J. F. (2010) Chemosensitization of cancer cells by siRNA using targeted nanogel delivery BMC Cancer 10, 10
33. Blackburn, W. H., Dickerson, E. B., Smith, M. H., McDonald, J. F., and Lyon, L. A. (2009) Peptide-Functionalized Nanogels for Targeted siRNA Delivery Bioconjugate Chem. 20, 960-968
34. van Geer, M. A., Bakker, C. T., Koizumi, N., Mizuguchi, H., Wesseling, J. G., Oude Elferink, R. P., and Bosma, P. J. (2009) Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo World J. Gastroenterol. 15, 2754-2762
35. Himanen, J. P., Goldgur, Y., Miao, H., Myshkin, E., Guo, H., Buck, M., Nguyen, M., Rajashankar, K. R., Wang, B., and Nikolov, D. B. (2009) Ligand recognition by A-class Eph receptors: Crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex EMBO Rep. 10, 722-728
36. Koide, S. and Sidhu, S. S. (2009) The importance of being tyrosine: Lessons in molecular recognition from minimalist synthetic binding proteins ACS Chem. Biol. 4, 325-334
37. Li, L., Chen, R., and Weng, Z. (2003) RDOCK: Refinement of rigid-body protein docking predictions Proteins 53, 693-707
38. Murai, K. K., Nguyen, L. N., Koolpe, M., McLennan, R., Krull, C. E., and Pasquale, E. B. (2003) Targeting the EphA4 receptor in the nervous system with biologically active peptides Mol. Cell. Neurosci. 24, 1000-1011
39. Chrencik, J. E., Brooun, A., Recht, M. I., Kraus, M. L., Koolpe, M., Kolatkar, A. R., Bruce, R. H., Martiny-Baron, G., Widmer, H., Pasquale, E. B., and Kuhn, P. (2006) Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity Structure 14, 321-330
40. Koolpe, M., Burgess, R., Dail, M., and Pasquale, E. B. (2005) EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity J. Biol. Chem. 280, 17301-17311
41. Lackmann, M., Mann, R. J., Kravets, L., Smith, F. M., Bucci, T. A., Maxwell, K. F., Howlett, G. J., Olsson, J. E., Vanden Bos, T., Cerretti, D. P., and Boyd, A. W. (1997) Ligand for EPH-related kinase (LERK) 7 is the preferred high affinity ligand for the HEK receptor J. Biol. Chem. 272, 16521-16530
42. Dail, M., Richter, M., Godement, P., and Pasquale, E. B. (2006) Eph receptors inactivate R-Ras through different mechanisms to achieve cell repulsion J. Cell Sci. 119, 1244-1254
43. Miao, H., Burnett, E., Kinch, M., Simon, E., and Wang, B. (2000) Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation Nat. Cell Biol. 2, 62-69
44. Huang, X., Wu, D., Jin, H., Stupack, D., and Wang, J. Y. (2008) Induction of cell retraction by the combined actions of Abl-CrkII and Rho-ROCK1 signaling J. Cell Biol. 183, 711-723
45. White, D. E., Kurpios, N. A., Zuo, D., Hassell, J. A., Blaess, S., Mueller, U., and Muller, W. J. (2004) Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction Cancer Cell 6, 159-170
46. Bartley, T. D., Hunt, R. W., Welcher, A. A., Boyle, W. J., Parker, V. P., Lindberg, R. A., Lu, H. S., Colombero, A. M., Elliott, R. L., and Guthrie, B. A. (1994) B61 is a ligand for the ECK receptor protein-tyrosine kinase Nature 368, 558-560
47. Wykosky, J., Palma, E., Gibo, D. M., Ringler, S., Turner, C. P., and Debinski, W. (2008) Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor Oncogene 27, 7260-7273